 "Zydus settles patent litigation related to seizure drug with US-based firm")
Zydus Cadila has settled a patent litigation related to the US-based Supernus Pharmaceuticals’ Trokendi XR (extended-release topiramate) capsules. “Cadila Healthcare Limited and its subsidiary Zydus Pharmaceutical (USA) Inc have finalised an agreement Supernus Pharmaceuticals to settle all outstanding patent litigation related to Trokendi XR (extended-release topiramate) capsules,” said Zydus in a press release.
Two sides were involved in a patent litigation regarding Zydus’ abbreviated new drug application (ANDA) seeking approval to market generic versions of Supernus' Trokendi XR capsules.
The settlement agreement permits Zydus to begin selling a generic version of Trokendi XR on January 1, 2023, or earlier under certain circumstances. The agreement will be submitted to the applicable governmental agencies.
Trokendi XR is prescribed for treat certain types of seizures (partial onset seizures and primary generalized tonic-clonic seizures) in people 6 years of age and older, and with other medicines to treat certain types of seizures (partial onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome) in adults and children 6 years and older.
“Supernus intends to continue its vigorous enforcement of its patent rights for Trokendi XR. Patent protection for Trokendi XR expires no earlier than 2027,” said Supernus in a press statement.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company focused on developing and commercialising products for the treatment of central nervous system (CNS) diseases.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%